Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01953263 · ClinicalTrials.gov registry record · Phase 1

Muscle Fiber Fragment Treatment for Urinary Incontinence

A Phase 1 study of Urinary Incontinence, sponsored by Wake Forest University.

Recruiting
Registry status
Phase 1
Development phase
10
Enrollment target
1
Study location

NCT01953263 is a Phase 1 study of Urinary Incontinence that is actively recruiting participants, run by Wake Forest University. The registered enrollment target is 10 participants, below the 262-participant average among 48 other Urinary Incontinence trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01953263, a Phase 1 study of Urinary Incontinence, is actively recruiting participants, sponsored by Wake Forest University.

RECRUITING
Registry status
Phase 1
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

This study is designed to evaluate the safety of autologous muscle fiber fragments for the treatment of urinary incontinence due to incompetent outlet (bladder neck/urethra).

Conditions Studied

Interventions

  • OTHER Autologous Muscle Fiber Fragments

Study Locations (1)

North Carolina

  • Wake Forest Urology Clinic - Winston-Salem

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2016-01
Est. Completion 2027-12
Phase Phase 1

Sponsor

Wake Forest University

100 total trials

What the Registry Record Tells You About NCT01953263

The ClinicalTrials.gov registry entry for NCT01953263 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 262-participant average among 48 other Urinary Incontinence trials with a reported enrollment target (96% lower). The listed sponsor is Wake Forest University, which has 100 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Urinary Incontinence appearing as the primary indexed condition, and to 1 intervention - of which Autologous Muscle Fiber Fragments is the first listed.

NCT01953263 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT01953263 about?

NCT01953263 is a clinical study titled "Muscle Fiber Fragment Treatment for Urinary Incontinence". This study is designed to evaluate the safety of autologous muscle fiber fragments for the treatment of urinary incontinence due to incompetent outlet (bladder neck/urethra).

What is the current status of trial NCT01953263?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2016-01. Estimated completion is 2027-12.

What conditions does trial NCT01953263 study?

This clinical trial studies the following conditions: Urinary Incontinence.

What interventions are being tested in trial NCT01953263?

The interventions under investigation include: Autologous Muscle Fiber Fragments (OTHER).

Who is sponsoring clinical trial NCT01953263?

This trial is sponsored by Wake Forest University, which has 100 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01953263 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Urinary Incontinence

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.